> Detailanzeige

Bauer, Nina; Löffler, Claudia; Oeznur, Oezlem; Uecker, Christine; Schlee, Christoph; Adamczyk, Alexandra; Elsenbruch, Sigrid; Pfuhlmann, Katrin; Reissmann, Ralf; Westendorf, Astrid; Keil, Thomas; Langhorst, Jost

Evaluation of a Multimodal Stress Management and Comprehensive Lifestyle Modification Program on Quality of Life and Gastrointestinal Symptoms in Patients with Crohn’s Disease: A Randomized Controlled Pilot Trial with 9-Month Follow-Up

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Evaluation of a Multimodal Stress Management and Comprehensive Lifestyle Modification Program on Quality of Life and Gastrointestinal Symptoms in Patients with Crohn’s Disease: A Randomized Controlled Pilot Trial with 9-Month Follow-Up
  • Beteiligte: Bauer, Nina; Löffler, Claudia; Oeznur, Oezlem; Uecker, Christine; Schlee, Christoph; Adamczyk, Alexandra; Elsenbruch, Sigrid; Pfuhlmann, Katrin; Reissmann, Ralf; Westendorf, Astrid; Keil, Thomas; Langhorst, Jost
  • Erschienen: S. Karger AG, 2024
  • Erschienen in: Digestion
  • Sprache: Englisch
  • DOI: 10.1159/000536659
  • ISSN: 0012-2823; 1421-9867
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; Stress and lifestyle factors impact the course of Crohn’s disease (CD). Our primary objective was to assess whether patients with CD benefit from a mind-body-medicine stress management and lifestyle modification (MBM) program. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; This 9-month two-arm pilot trial was conducted in Bamberg, Germany (2020–2021). Patients (18–75 years) with mild to moderate activity of CD and stable medication were enrolled and randomly assigned to either a 10-week MBM program (intervention group, IG) or a single 90-min education session (waiting list control group, CG). Primary endpoints were quality of life (IBDQ) and disease activity (HBI). Secondary endpoints were emotional distress, core self-evaluation, and inflammatory biomarkers 3 and 9 months after baseline assessment. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; We analyzed data from 37 patients (IG: &lt;i&gt;n&lt;/i&gt; = 19, mean ± SD age 49.6 ± 13.1 years, 68% female; CG: 18, 46.8 ± 11.4, 67% female). Immediately after the intervention, 79% (IG) and 44% (CG) experienced a clinically relevant improvement (IBDQ score ≥16 points). This was similar after 9 months (63% vs. 44%). There was no difference in disease activity (3 months: &lt;i&gt;p&lt;/i&gt; = 0.082, 95% CI −1.3 to 2.6; 9 months: &lt;i&gt;p&lt;/i&gt; = 0.251, 95% CI −1.2 to 2.5). Secondary outcomes indicated improvements in emotional distress, core self-evaluation, erythrocyte sedimentation rate after three and in emotional distress, T-cell profiling in the blood, and fecal lactoferrin and calprotectin group after 9 months in the IG. &lt;b&gt;&lt;i&gt;Conclusion:&lt;/i&gt;&lt;/b&gt; Our study suggested benefits of a multimodal stress management and lifestyle modification program for patients with CD. Larger trials are needed to determine if the program can supplement or at least partially replace pharmacological treatment approaches. </jats:p>